

Study Description

The CommonMind Consortium is a public-private partnership bringing together disease area knowledge, large scale and well-curated brain sample collections, data management and analysis expertise. The consortium has as a goal to generate and analyze large-scale genomic data from human subjects with neuropsychiatric disease and to make these data and the associated analytical results broadly available to qualified investigators. The consortium is generating multiple data modalities (e.g. RNA and DNA sequencing, genotyping, epigenetics) across several brain regions from individuals with schizophrenia, bipolar disorder, and unaffected controls on a collection of more than 1,000 individuals.

Funding from Takeda Pharmaceuticals Company Limited, F. Hoffman-La Roche Ltd and NIH grants R01MH085542, R01MH093725, P50MH066392, P50MH080405, R01MH097276, RO1MH075916, P50M096891, P50MH084053S1, R37MH057881, R37MH057881S1, HHSN271201300031C, AG02219, AG05138 and MH06692 to Pamela Sklar, Joseph Buxbaum, Vahram Haroutunian, Eric Schadt, (Icahn School of Medicine at Mount Sinai), Chang-Gyu Hahn (University of Pennsylvania), David Lewis and Bernie Devlin (University of Pittsburgh), supported the data generation and analysis of brain tissue originating from the following four brain banks: the Mount Sinai NIH Brain and Tissue Repository, the University of Pennsylvania Alzheimer's Disease Core Center, the University of Pittsburgh NeuroBioBank and Brain and Tissue Repositories and the NIMH Human Brain Collection Core.

CMC Leadership: Pamela Sklar, Joseph Buxbaum (Icahn School of Medicine at Mount Sinai), Bernie Devlin, David Lewis (University of Pittsburgh), Raquel Gur, Chang-Gyu Hahn (University of Pennsylvania), Keisuke Hirai, Hiroyoshi Toyoshiba (Takeda Pharmaceuticals Company Limited), Enrico Domenici, Laurent Essioux (F. Hoffman-La Roche Ltd), Lara Mangravite, Mette Peters (Sage Bionetworks) Thomas Lehner, Barbara Lipska (NIMH).

These additional people have made significant contributions towards the generation and analysis of the data: commonmind.org

Acknowledgement

Data were generated as part of the CommonMind Consortium supported by funding from Takeda Pharmaceuticals Company Limited, F. Hoffman-La Roche Ltd and NIH grants R01MH085542, R01MH093725, P50MH066392, P50MH080405, R01MH097276, RO1-MH-075916, P50M096891, P50MH084053S1, R37MH057881 and R37MH057881S1, HHSN271201300031C, AG02219, AG05138 and MH06692. Brain tissue for the study was obtained from the following brain bank collections: the Mount Sinai NIH Brain and Tissue Repository, the University of Pennsylvania Alzheimer's Disease Core Center, the University of Pittsburgh NeuroBioBank and Brain and Tissue Repositories and the NIMH Human Brain Collection Core. CMC Leadership: Pamela Sklar, Joseph Buxbaum (Icahn School of Medicine at Mount Sinai), Bernie Devlin, David Lewis (University of Pittsburgh), Raquel Gur, Chang-Gyu Hahn (University of Pennsylvania), Keisuke Hirai, Hiroyoshi Toyoshiba (Takeda Pharmaceuticals Company Limited), Enrico Domenici, Laurent Essioux (F. Hoffman-La Roche Ltd), Lara Mangravite, Mette Peters (Sage Bionetworks), Thomas Lehner, Barbara Lipska (NIMH).

Data Access Instructions

The CommonMind Consortium data is distributed through the Sage Bionetworks Synapse system. Before submitting a data access request to NRGR, please see instructions for use of Controlled Access data in the CommonMind Consortium Knowledge Portal (<https://www.synapse.org/#!/Synapse:syn2759792/wiki/197282>).